CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer (OC).
  
  LEARNING OBJECTIVES

  • Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC, and provide appropriate counsel regarding personalized treatment recommendations.
  • Assess available clinical trial data with and newly adapted indications for the use of FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to optimally and appropriately incorporate these agents into current management algorithms.
  • Evaluate the biological rationale for and published research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings for OC management.
  • Appraise biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
  • Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods of testing for this newly relevant biomarker and the current role of novel approaches in therapeutically exploiting it.
  • Appreciate the side effects associated with various systemic therapies commonly employed in the management of OC, and use this information to develop supportive care plans for patients who receive these agents.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for OC, and appropriately counsel patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SGO24Ovarian/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Joyce F Liu, MD, MPH
  Associate Chief and Director of Clinical Research
  Division of Gynecologic Oncology
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, GSK, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Regeneron Pharmaceuticals Inc, Zentalis Pharmaceuticals; Consulting Agreement: Bristol Myers Squibb; Trial Support to My Institution for Study Conduct: Aravive Inc, Arch Oncology, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Clovis Oncology, GSK, Impact Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Vigeo Therapeutics, Volastra Therapeutics Inc, Zentalis Pharmaceuticals.
  
  Mansoor Raza Mirza, MD
  Chief Oncologist
  Copenhagen University Hospital
  Medical Director
  Nordic Society of Gynaecological Oncology – Clinical Trial Unit
  Vice President, European Society of Gynaecological Oncology
  Copenhagen, Denmark
  
  Advisory Committees: Allarity Therapeutics, BIOCAD, BioNTech SE, Daiichi Sankyo Inc, Eisai Inc, GSK, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, MSD, Zai Lab; Consulting Agreements: Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, BIOCAD, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, MSD, Novartis, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Zai Lab; Stock Options/Stock — Public Companies: Karyopharm Therapeutics, Sera Prognostics.
  
  David M O'Malley, MD
  Director and Professor
  Division of Gynecologic Oncology in Obstetrics and Gynecology
  John G Boutselis Chair in Gynecologic Oncology
  The Ohio State University and The James Comprehensive Cancer Center
  Columbus, Ohio
  
  Advisory Committees and Consulting Agreements (Personal Fees): AbbVie Inc, Adaptimmune, Agenus Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Duality Biologics, Eisai Inc, Elevar Therapeutics, Exelixis Inc, F Hoffmann-La Roche Ltd, Genelux Corporation, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Imvax Inc, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, OncoC4, Onconova Therapeutics Inc, Regeneron Pharmaceuticals Inc, Replimune, Roche Diagnostics, R-Pharm US, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Clovis Oncology, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Rubius Therapeutics, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Nonrelevant Financial Relationships: GOG Foundation Inc, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG, SWOG.
  
  VIDEO PARTICIPANTS — Deborah K Armstrong, MD — Consulting Agreement (Uncompensated Consulting): Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Eisai Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Floor J Backes, MD — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, BioNTech SE, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, GSK, ImmunoGen Inc, Merck. Rachel N Grisham, MD — Consulting Agreements: AstraZeneca Pharmaceuticals LP, GSK, Myriad Genetic Laboratories Inc, Natera Inc; Contracted Research: Context Therapeutics, Corcept Therapeutics, Pfizer Inc, SpringWorks Therapeutics Inc, Verastem Inc. Ritu Salani, MD, MBA — Advisory Committees: Eisai Inc, GSK, ImmunoGen Inc, Merck, Regeneron Pharmaceuticals Inc, Seagen Inc.
  
  MODERATOR
  Kathleen N Moore, MD, MS
  Deputy Director
  Associate Director, Clinical Research
  Virginia Kerley Cade Chair in Developmental Therapeutics
  Co-Director, Cancer Therapeutics Program Stephenson Cancer Center at the University of Oklahoma HSC
  Associate Director, GOG Partners
  Board of Directors, GOG Foundation
  Oklahoma City, Oklahoma
  
  Advisory Committees: Aadi Bioscience, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Caris Life Sciences, Clovis Oncology, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Panavance Therapeutics, Regeneron Pharmaceuticals Inc, VBL Therapeutics, Verastem Inc, Zentalis Pharmaceuticals; Consulting Agreements: Aadi Bioscience, Caris Life Sciences, Duality Biologics, Eisai Inc, Mersana Therapeutics Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Genentech, a member of the Roche Group, GSK, Lilly, PTC Therapeutics.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, and Mural Oncology Inc.
  
  Release date: April 2024
  Expiration date: April 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.